Enzymatica AB (publ) (STO:ENZY)

Market Cap	631.11M -12.5%
Revenue (ttm)	53.06M +9.6%
Net Income	-47.34M
EPS	-0.20
Shares Out	242.74M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	57,127
Open	2.510
Previous Close	2.520
Day's Range	2.430 - 2.600
52-Week Range	1.600 - 3.400
Beta	-0.37
Analysts	n/a
Price Target	2.69 (+3.46%)
Earnings Date	Jul 16, 2026

About Enzymatica AB

Enzymatica AB (publ), a life science company, develops and sells medical devices for infection-related diseases. The company’s product includes ColdZyme, a mouth spray that protects against the upper respiratory viruses that can cause cold and flu symptoms. It also provides enzyme formulations for skin care. The company was incorporated in 2007 and is headquartered in Lund, Sweden.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2007
• Employees: 21
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: ENZY

Financial Performance

In 2025, Enzymatica AB's revenue was 53.90 million, an increase of 18.27% compared to the previous year's 45.58 million. Losses were -51.89 million, -2.42% less than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jun 16, 2026

Data Sources Report a data error